InKine Pharmaceutical Elects Robert A. Vukovich, Ph.D. to Board of Directors.BLUE BELL, Pa.--(BUSINESS WIRE)--Sept. 9, 1998--InKine Pharmaceutical Company, Inc., (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :INKP) today announced the election of Robert A. Vukovich, Ph.D., founder of Roberts Pharmaceutical Corporation to its Board of Directors. Dr. Vukovich, 55, currently serves as Executive Chairman of Roberts Pharmaceutical Corporation and has almost 30 years of drug development experience in the pharmaceutical industry. He previously held positions at Warner-Lambert, Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were and the Revlon Health Care Group. As Chairman, President and Chief Executive Officer of Roberts, Dr. Vukovich pursued a strategy of novel compound acquisition for large pharmaceutical markets. He built a sales and marketing infrastructure and acquired manufacturing and distribution facilities. Additionally, he established a number of strategic alliances with major multinational pharmaceutical corporations. "We are pleased to have someone with Dr. Vukovich's vision and expertise in product acquisition and development join our board of directors," said Leonard Jacob Jacob (jā`kəb), in the Bible, ancestor of the Hebrews, the younger of Isaac and Rebecca's twin sons; the older was Esau. In exchange for a bowl of lentil soup, Jacob obtained Esau's birthright and, with his mother's help, received the blessing , M.D., Ph.D., Chairman and Chief Executive Officer of InKine. "InKine will greatly benefit from his knowledge and tremendous experience in the pharmaceutical industry." InKine Pharmaceutical Company, Inc., is a publicly traded biopharmaceutical company with two late-stage clinical compounds: a purgative purgative /pur·ga·tive/ (purg´it-iv) cathartic (1, 2). pur·ga·tive n. An agent used for purging the bowels. adj. Tending to cause evacuation of the bowels. product for colonoscopies and other procedures and uses; and a steroid molecule for treatment of ITP ITP - Intent to Package . The Company is focused on the diagnosis and treatment of cancer and autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , and has the additional strategy of acquiring late-stage drug candidates with short time lines to commercialization. Support of early-stage product opportunities comes through its university-based sponsored research agreements. CONTACT: InKine Pharmaceutical Company, Inc. Robert F. Apple, VP, Finance & Administration 610/260-9350 or Wolfe Axelrod Ax·el·rod , Julius 1912-2004. American biochemist and pharmacologist. He shared a 1970 Nobel Prize for studies of the ways in which different substances affect neural impulses. Associates Don Weinberger, 212/370-4500 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion